Liberate Bio, Inc., a biotechnology company developing genetic medicines that deliver RNA therapies directly to immune cells, announces that it has secured exclusive and non-exclusive licenses to key ...

Legend Biotech said Tuesday all six patients in a Phase 1 study of its in vivo CAR-T responded to the lymphoma treatment.

Introducing the first in vivo data using RetroT, a first-in-class all-mRNA platform for stable gene delivery without viral components Demonstrating CREATE's leadership in in vivo immune cell ...

ASH 2025 data on KLN-1010 suggest that off-the-shelf, in vivo CAR T therapy could significantly expand access to cellular therapy in multiple myeloma by reducing manufacturing, treatment delays, and ...

This webinar will highlight how circular RNA overcomes key challenges in in vivo CAR-T therapy, with case examples from YXgene’s circRNA platform. In vivo CAR-T therapy is emerging as a transformative ...

Induced pluripotent stem cells (iPSCs) are derived from adult cells, such as skin or blood cells, which have been “reprogrammed” back to a stem-cell-like state. This transformation grants them the ...

ROCHESTER, Minn., December 23, 2025--(BUSINESS WIRE)--Vyriad, Inc., a clinical-stage biotechnology company developing targeted genetic therapies for cancer and other serious diseases, today announced ...

Early phase 1 data suggest that in vivo, off-the-shelf CAR T therapy may be feasible in multiple myeloma, offering the promise of faster, less toxic treatment without lymphodepletion while raising ...